

# The development, testing and evaluation of a COVID-19 fundamental nursing care protocol

<b>Submission date</b> 10/08/2020	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 09/09/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 06/11/2023	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Patient experience of care is correlated with safety, clinical effectiveness, care quality, treatment outcomes and reduced overall service use. Currently, no international evidence-based guidelines exist for nursing hospitalised patients with SARS-CoV-2 who are not invasively ventilated, leading to potential variations in patient experience, treatment outcomes, care quality and costs. The aim of this study is to evaluate an evidence-based nursing protocol for patients with the SARS-CoV-2 virus, compared to care as usual, in terms of patients' reported experience of transactional and relational nursing care, care quality, treatment outcomes and costs.

### Who can participate?

UK hospital trusts providing care for patients with COVID-19, patients who are not invasively ventilated admitted for care by these Trusts, and the nurses caring for these patients

### What does the study involve?

Trusts will be allocated at random to one of two groups, one to implement the protocol and the other to continue to deliver nursing care as usual. In Trusts allocated to the COVID-NURSE protocol group, nurses and care assistants caring for patients with COVID-19 will need to undertake a three-hour online education programme about the protocol. Senior managers and nurse leaders will be required to support nursing teams to use the protocol. The researchers will provide support to managers and leaders together with materials supporting the protocol. The research team and clinical research nurses will collect data in both groups from non-invasively ventilated patients with COVID-19 on their experiences of care. They will also collect routine health outcomes data and questionnaires from nurses delivering care.

### What are the possible benefits and risks of participating?

The study is comparing a COVID-specific nursing protocol with usual care. Participants in the experimental group of the study may benefit from receiving this protocol and no existing treatment will be withheld from any participants in either group of the study. Therefore, the researchers do not believe that participation in the study is a risk to participants. Participants may withdraw from the study at any time without prejudicing their treatment, care or employment.

Where is the study run from?  
University of Exeter (UK)

When is the study starting and how long is it expected to run for?  
July 2020 to January 2022 (updated 15/09/2021, previously: October 2021)

Who is funding the study?  
National Institute for Health Research (NIHR) (UK)

Who is the main contact?  
Prof. David Richards  
D.a.richards@exeter.ac.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof David Richards

**ORCID ID**  
<https://orcid.org/0000-0002-8821-5027>

**Contact details**  
University of Exeter  
St Luke's Campus  
Heavitree Road  
Exeter  
United Kingdom  
EX1 2LU  
+44 (0)1392 724615  
d.a.richards@exeter.ac.uk

## Additional identifiers

**Integrated Research Application System (IRAS)**  
287288

**Central Portfolio Management System (CPMS)**  
46874

**Protocol serial number**  
MR/V02776X/1

## Study information

**Scientific Title**

COVID-NURSE. The development and evaluation of a fundamental nursing care protocol for hospitalised patients with the SARS-CoV-2 virus not invasively ventilated on patients' experience of care: a cluster randomized controlled trial

## **Acronym**

COVID-NURSE

## **Study objectives**

Current study hypothesis as of 27/05/2021:

To undertake a cluster randomised controlled superiority trial to evaluate an evidence-based nursing protocol for patients with the SARS-CoV-2 virus, compared to care as usual, in terms of patients' reported experience of transactional and relational nursing care, care quality, treatment outcomes and costs.

---

Previous study hypothesis:

To undertake a rapid cycle (Johnson et al., 2015) cluster randomised controlled superiority trial to evaluate an evidence-based nursing protocol for patients with the SARS-CoV-2 virus, compared to care as usual, in terms of patients' reported experience of transactional and relational nursing care, care quality, treatment outcomes and costs.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Approved 31/07/2020, University of Exeter Medical School (Knowledge Spa, Royal Cornwall Hospital, Truro, Cornwall, TR1 3HD, UK; +44 (0)1872 256460; c.barkle@exeter.ac.uk), ref: 20/07/256

## **Study design**

Cluster randomized controlled trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

COVID-19 (SARS-CoV-2 infection)

## **Interventions**

To ensure allocation concealment, the researchers will undertake randomisation through the use of an externally administered, password-protected randomisation website independently developed and maintained by the UKCRC-registered University of Exeter Clinical Trials Unit. They will pair the 18 sites according to admission case rates, hospital type and patient ethnic diversity and, for each of the nine pairs, randomly allocate one site to the intervention group and

one site to the control group. Allocation will be conducted over three cycles of six sites (three pairs) each.

Experimental intervention: care as usual plus the clinical protocol developed in stage 1. After each wave of implementation and drawing on process evaluation findings, the researchers will modify their clinical protocol accordingly and embed the new version of the protocol in each subsequent experimental intervention cycle site. They will embed the protocol in intervention sites before each cycle via staff education, reminders and leadership-directed strategies successfully used in a previous cluster randomised controlled trial to significantly increase handwashing by nurses and care staff. They will monitor protocol adherence and fidelity as part of the process evaluation, amending their educational and leadership strategies accordingly before each subsequent rapid cycle wave.

Control: care as usual only

The intervention duration will be a minimum of 72 hours. Follow up will be also after a minimum of 72 hours, ensuring that patient-participants are able to report their experience of being nursed using the nursing protocol for a minimum of 72 hours.

### **Intervention Type**

Behavioural

### **Primary outcome(s)**

Patient experience measured using the Quality from the Patient's Perspective, and the Relational Aspects of Care Questionnaires at a minimum of 72 hours after exposure to the nursing care protocol

### **Key secondary outcome(s)**

Current secondary outcome measures as of 19/10/2020:

Measured after a minimum of 72 hours after protocol exposure:

1. Care quality (prevalence of level 3 and 4 pressure sores, frequency of patient falls, frequency of medication errors) measured using the United Kingdom National Health Service Ward to Board dashboard
2. Functional ability measured using the Barthell Index
3. Treatment outcomes measured using the WHO Clinical Progression Scale
4. Depression measured using the PHQ-2
5. Anxiety measured using the GAD-2
6. Health utility measured using the EQ5D
7. Nurse outcomes measured using the Measure of Moral Distress for Health Care Professionals

Previous secondary outcome measures:

Measured after a minimum of 72 hours after protocol exposure:

1. Care quality measured using the United Kingdom National Health Service Ward to Board dashboard
2. Functional ability measured using the Barthell Index
3. Treatment outcomes measured using the WHO Clinical Progression Scale
4. Nurse outcomes measured using the Measure of Moral Distress for Health Care Professionals
5. Health utility measured using the EQ5D

### **Completion date**

31/01/2022

# Eligibility

## Key inclusion criteria

1. Patients who are not invasively ventilated
2. Aged  $\geq 18$  years
3. Currently hospitalised and treated for infection with the SARS-CoV-2 virus
4. Received nursing care for a minimum of 72 hours during their current admission

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Lower age limit

18 years

## Sex

All

## Total final enrolment

999

## Key exclusion criteria

1. Patients who are invasively ventilated
2. Participants unable to give informed consent

## Date of first enrolment

01/11/2020

## Date of final enrolment

24/12/2021

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

**Royal Devon and Exeter NHS Foundation Trust**

Royal Devon and Exeter Hospital

Barrack Road

Exeter

United Kingdom  
EX2 5DW

## Sponsor information

### Organisation

University of Exeter

### ROR

<https://ror.org/03yghzc09>

## Funder(s)

### Funder type

Government

### Funder Name

National Institute for Health Research

### Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

Participants will be identified by a unique study ID. Personal identifiable data including date of birth and NHS number may be collected but will be stored separately to research data and will be destroyed as per applicable regulations when the project is concluded. Data will be managed by the UKCRC registered Exeter Clinical Trials Unit (ExeCTU) following GDPR and data protection guidelines and all relevant Clinical Trial Regulations. All data will be anonymised prior to publication. Data will be collected and stored electronically in accordance with the Data Protection Act 2018 and ICH GCP E6 R2. ExeCTU will use Redcap Cloud Electronic Data Capture

System to collect all case report data. This system is validated to ISO27001 standards, backed up and maintained in Europe. This system is fully compliant to GDPR regulations and managed by ExeCTU. Any additional study data will be stored and backed up on the secure ExeCTU servers, maintained by ExeCTU. Data will be cleaned and validated appropriately and a full Data Protection Impact Assessment (DPIA) will be undertaken along with the development of a comprehensive Data Management Plan (DMP) before the first participant is recruited. Where data are disseminated (e.g. via report, presentation or publication), they will be anonymised. The researchers will align all confidentiality and data handling with the Caldicott Principles. Anonymised data will be stored indefinitely on a research data storage system provided by the University of Exeter called Open access Research Exeter (ORE) for archiving (<http://www.exeter.ac.uk/research/openresearch/policies/ore/>).

## IPD sharing plan summary

Stored in repository

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/11/2021	14/02/2022	Yes	No
<a href="#">Protocol article</a>		26/05/2021	28/05/2021	Yes	No
<a href="#">Participant information sheet</a>	Consent form version 4.0	12/01/2021	06/11/2023	No	Yes
<a href="#">Participant information sheet</a>	Consent form version 5.0	25/01/2021	06/11/2023	No	Yes
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes